Detecting primitive hematopoietic stem cells in total nucleated and mononuclear cell fractions from umbilical cord blood segments and units

详细信息    查看全文

• 作者：John Patterson (1)
  Cally H Moore (2)
  Emily Palser (3)
  Jason C Hearn (4)
  Daniela Dumitru (4)
  Holli A Harper (4)
  Ivan N Rich (4)
  
  1. Beth-Ell College of Nursing and Health Science ; University of Colorado at Colorado Springs ; Colorado Springs ; Colorado ; USA
  2. Department of Biological Engineering ; University of Colorado ; Boulder ; Colorado ; USA
  3. Department of Biology ; University of Colorado at Colorado Springs ; Colorado Springs ; Colorado ; USA
  4. HemoGenix ; Inc ; 1485 Garden of the Gods Road ; Suite 152 ; Colorado Springs ; CO ; 80906 ; USA
  
• 关键词：Colony ; forming unit ; ATP bioluminescence ; Proliferation assay ; Umbilical cord blood ; Stem cell transplantation ; Total nucleated cell fraction ; Stem cell processing ; Viability ; Segment ; Umbilical cord blood unit
• 刊名：Journal of Translational Medicine
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：13
• 期：1
• 全文大小：897 KB
• 参考文献：1. Messner, HA, Fauser, AA, Lepine, J, Martin, M (1980) Properties of human pluripotent hematopoietic progenitors. Blood Cells 6: pp. 595-607
  2. Hodgson, GS, Bradley, TR, Radley, JM (1982) The organization of hematopoietic tissue as inferred from the effects of 5-fluoruracil. Exp Hemat 10: pp. 26-35
  3. Johnson, GR (1984) Methodology for the identification and characterization of hematopoietic cells. Clonal assays for multipotential hematopoietic cells in vitro. Bibl. Haematol 48: pp. 63-80
  4. Bradley, TR, Hodgson, GS, Bertoncello, I (1990) High proliferative potential colony forming cells. Methods Mol Biol 5: pp. 289-97
  5. Stephenson, JR, Axelrad, AA, McLeod, DL, Shreeve, MM (1971) Induction of colonies of hemoglobin-synthesizing cells by erythropoietin in vitro. Proc Natl Acad Sci USA 68: pp. 1542-6 CrossRef
  6. Iscove, NN, Sieber, F, Winterhalter, KH (1974) Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A. J Cell Physiol 83: pp. 309-20 CrossRef
  7. Cottler-Fox, M Hematopoietic progenitor cells. In: Burt, RK, Deeg, HJ, Lothian, ST, Santos, GW eds. (1996) On Call in 鈥?Bone Marrow Transplantation. Chapman and Hall, London, UK, pp. 69-75
  8. Broxmeyer, HE (2010) Cord blood hematopoietic stem cell transplantation. StemBook.org. Harvard Stem Cell Institute, Cambridge, MA
  9. Ruggeri, A, Labopin, M, Sormani, MP, Sanz, G, Sanz, J, Volt, F (2014) Engraftment kinetics and graft failure after single umbilical cord blood transplantation using myeloablative conditioning regimen. Haematologica. 99: pp. 1509-15 atol.2014.109280" target="_blank" title="It opens in new window">CrossRef
  10. Page, KM, Xhang, L, Mendizabal, A, Wease, S, Carter, S, Gentry, T (2011) Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single center analysis of 435 cord blood transplants. Biol Blood Marrow Transplant 17: pp. 1362-74 CrossRef
  11. Sutherland, DR, Keating, A, Nayar, R, Anania, S, Stewart, AK (1994) Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. Exp Hematol 22: pp. 1003-10
  12. Gluckman, E, Broxmeyer, HA, Auerbach, AD, Friedman, HS, Douglas, GW, Devergie, A (1989) Hematopoietic reconstitution in a patient with Fanconi鈥檚 anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 321: pp. 1174-8 CrossRef
  13. Bradley, TR, Metcalf, D (1966) The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 44: pp. 287-99 CrossRef
  14. Pluznik, DH, Sachs, L (1966) The induction of clones of normal mast cells by a substance from conditioned medium. Exp Cell Res 43: pp. 553-63 CrossRef
  15. Pike, BL, Robinson, WA (1970) Human bone marrow colony growth in agar-gel. J Cell Physiol 76: pp. 77-84 CrossRef
  16. Kriegler, AB, Bradley, TR, Hodgson, GS, McNiece, IK (1987) A colorimetric liquid culture assays of a growth factor for primitive murine macrophage progenitor cells. J Immunol Meth 103: pp. 93-102 CrossRef
  17. Monner, DA (1988) An assay for growth of mouse bone marrow cells in microtiter liquid culture using the tetrazolium salt MTT, and its application to studies of myelopoiesis. Immunol Lett 19: pp. 261-8 CrossRef
  18. Horowitz, D, King, AG (2000) Colorimetric determination of inhibition of hematopoietic progenitor cells in soft agar. J Immunol Meth 244: pp. 49-58 CrossRef
  19. Rich, IN, Hall, KM (2005) Validation and development of a predictive paradigm for hemotoxicity using a multifunctional bioluminescence colony-forming proliferation assay. Tox Sci. 87: pp. 427-41 CrossRef
  20. Reems, J-A, Hall, KM, Gebru, LH, Taber, G, Rich, IN (2008) Development of a novel assay to evaluate the functional potential of umbilical cord blood progenitors. Transfusion. 48: pp. 620-8 CrossRef
  21. Crouch, SP, Kozlowski, R, Slater, KJ, Fletcher, J (1993) The use of ATP bioluminescence s a measure of cell proliferation and cytotoxicity. J Immunol Meth 160: pp. 81-8 CrossRef
  22. Solves, P, Planelles, D, Mirabet, V, Blanquer, A, Carbonell-Uberos, F (2013) Qualitative and quantitative cell recovery in umbilical cord blood processed by two automated devices in routine cord blood banking: a comparative study. Blood Transfus. 11: pp. 405-11
  23. Harris, DT (2008) Collection, processing, and banking of umbilical cord blood stem cells for clinical use in transplantation and regenerative medicine. Labmedicine 39: pp. 173-8
  24. Basford, C, Forraz, N, Habibollah, S, Hanger, K, McGuckin, C (2010) The cord blood separation league table: a comparison of major clinical grade harvesting techniques for cord blood stem cells. Intl J Stem Cell 3: pp. 32-45 CrossRef
  25. Aroviita, PI, Teramo, K, Westman, P, Hiilesmaa, V, Kekomaki, R (2003) Associations among nucleated cell, CD34+ cell and colony-forming cell contents in cord blood units obtained through a standardized banking process. Vox Sang 84: pp. 219-27 CrossRef
  26. George, TJ, Sugrue, MW, George, SN, Wingard, JR (2006) Factors associated with parameters of engraftment potential of umbilical cord blood. Transfusion. 46: pp. 1803-12 CrossRef
  27. Spellman, S, Hurley, CK, Brady, C, Phillips-Johnson, L, Chow, R, Laughlin, M (2011) Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood. National Marrow Donor Program Advisory Group. Cytotherapy 13: pp. 848-55 CrossRef
  28. Pamphillon, D, Selogie, E, McMenna, D, Cancelas-Peres, JA, Szczepiorkowski, ZM, Cacher, R (2013) Current practices and prospects for standardization of the hematopoietic colony-forming unit assay: a report by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Cytotherapy 15: pp. 255-62 CrossRef
  29. Rich, IN, Kubanek, B (1982) The effect of reduced oxygen tension on colony formation of erythropoietic cells in vitro. Brit J Haematol 52: pp. 579-88 CrossRef
  30. Olaharski, AJ, Uppal, H, Cooper, M, Platz, S, Zabka, TS, Kolaja, KL (2009) In vitro to in vivo concordance of a high throughput assay for bone marrow toxicity across a diverse set of drug candidates. Toxicol Let 188: pp. 98-103 CrossRef
  31. Hall, KM, Rich, IN Bioluminescence assays for assessing potency of cellular therapeutic products. In: Areman, EM, Loper, K eds. (2009) Cellular therapy: principles, methods and regulations. AABB. ISBN 978-1-56395-296-8, Bethesda, MD, pp. 581-91
  32. Hall KM, Harper H, Rich IN. Hematopoietic stem cell potency for cellular therapeutic transplantation, advances in hematopoietic stem cell research. Rosana Pelayo (Ed.), 2012, 383鈥?06. ISBN: 978-953-307-930-1, InTech, Available from: atopoietic-stem-cell-research/hematopoietic-stem-cell-potency-for-cellular-therapeutic-transplantation" class="a-plus-plus">http://www.intechopen.com/books/advances-in-hematopoietic-stem-cell-research/hematopoietic-stem-cell-potency-for-cellular-therapeutic-transplantation.
  33. U.S. Food and Drug Administration (FDA). Guidance for Industry. Bioanalytical method validation. (2001). atoryInformation/Guidances/ucm070107.pdf" class="a-plus-plus">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.
  34. Rich, IN Measurement of hematopoietic stem cell proliferation, self-renewal, and expansion potential. In: Rich, IN eds. (2015) Stem Cell Protocols, Methods Mol Biol. pp. 7-17 CrossRef
  35. Rich IN. Potency, proliferation and engraftment potential of stem cell therapeutics: The relationship between potency and clinical outcome for hematopoietic stem cell products. J Cell Sci Ther. 2013. http://dx.doi.org/10.4172/2157-7013.S13-001.
  36. Harper H, Rich IN. Measure the potency of a stem cell therapeutic. In Stem Cell Protocols, Methods Mol Biol. Edited by Rich IN. 2015, 1235:33鈥?8. doi:10.1007/978-1-4939-1785-3_4.
  37. Rich IN. Tissue engineering: Propagation and Potency Evaluation. In: Translational Regenerative Medicine, (Ed) Atala A. (2015) Elsevier. http://dx.doi.org/10.1016/B978-0-12-410396-2.00010-4.
  38. Gutensohn, K, Odendahl, M, Kersten, JF, Tonn, T (2013) Validation of cord blood split products prepared by an automated method. Transfus Med 23: pp. 48-51 148.2012.01191.x" target="_blank" title="It opens in new window">CrossRef
  39. Rodriguez, L, Garcia, J, Querol, S (2005) Predictive utility of the attached segment in the quality control of a cord blood graft. Bio Blood Marrow Transplant 11: pp. 247-51 CrossRef
  40. Vos, J, Birebent, B, Faucher, C, Giet, O, Hicheri, Y, Lemarie, C (2014) Quality controls on cord blood unit contiguous segments: Recommendation of the SFGM-TC. Path Biol 62: pp. 218-20 atbio.2014.05.005" target="_blank" title="It opens in new window">CrossRef
  41. Barker, JN, Bya, C, Scaradavou, A (2011) How I treat: the selection and acquisition of unrelated cord blood grafts. Blood 117: pp. 2332-9 CrossRef
  42. Zumpe, C, Bachmann, CL, Metzger, AU, Wiedermann, N (2010) Comparison of potency assays using different read-out systems and their suitability for quality control. J Immunol Meth 360: pp. 129-40 CrossRef
  43. Rich, IN (2003) In vitro hematotoxicity testing in drug development: a review of past, present and future applications. Curr Opinion in Drug Disc Develop 6: pp. 100-9
  44. Pretti, RA, Chan, WS, Kurtzburg, J, Dornsife, RE, Wallace, PK, Furlage, R (2014) Multi-site evaluation of the BD stem cell enumeration kit for CD34+ cell enumeration on the BD FACSCanta II and BD FACSCalibur flow cytometers. Cytotherapy 16: pp. 1558-74 CrossRef
  45. Pope B, Hokin B, Grant R. Effect of umbilical cord blood prefreeze variables on postthaw viability. Transfusion 2014, doi:10.1111/trf.12873.
  46. Salge-Bartels, U, Huber, HM, Kleiner, K, Volkers, P, Seitz, R, Heiden, M (2009) Evaluation of quality parameters for cord blood donations. Transf Med Hemother 36: pp. 317-24 CrossRef
  47. Scaradavou, A, Smith, KM, Hawke, R, Schaible, A, Abboud, M, Kerman, NA (2010) Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation. Biol Blood Marrow Transplant 16: pp. 500-8 CrossRef
  48. Querol, S, Gomez, SG, Pagliuca, A, Torrabadella, M, Madrigal, JA (2010) Quality rather than quantity: the cord blood bank dilemma. Bone Marrow Transplant 50: pp. 265
  49. U.S. Food and Drug Administration (FDA). Guidance for Industry. Biologics license applications for minimally manipulated unrelated allogeneic placenta/umbilical cord blood intended for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system. (2014). atoryInformation/Guidances/CellularandGeneTherapy/UCM357135.pdf" class="a-plus-plus">http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM357135.pdf.
  50. Page, KM, Mendizabal, A, Betz-Stablein, B, Wease, S, Shoulars, K, Gentry, T (2014) Optimizing donor selection for public cord blood banking: influence of maternal, infant, and collection characteristics on cord blood quality. Transfusion 54: pp. 340-52
  51. Bart, T, Boo, M, Balabanova, S, Fisher, Y, Nicolosco, G, Foeken, L (2013) Selection and sustainability: impact on selection of the cord blood units from the United States and Swiss registries on the cost of banking operations. Transfus Med Hemother 40: pp. 14-20 CrossRef
  52. Allen D, Petraszko T, Elmoazzan H, Smith S. A review of factors influencing the banking of collected umbilical cord blood units. Stem Cell International 2013, http://dx.doi.org/10.1155/2013/463031.
  53. National Marrow Donor Program (NMDP). atch.org/transplant-basics/cord-blood-and-transplants" class="a-plus-plus">http://bethematch.org/transplant-basics/cord-blood-and-transplants.
  
• 刊物主题：Biomedicine general; Medicine/Public Health, general;
• 出版者：BioMed Central
• ISSN：1479-5876

文摘

Background Rare hematopoietic stem cell populations are responsible for the transplantation engraftment process. Umbilical cord blood (UCB) is usually processed to the total nucleated cell (TNC), but not to the mononuclear cell (MNC) fraction. TNC counts are used to determine UCB unit storage, release for transplantation and correlation with time to engraftment. However, the TNC fraction contains varying concentrations of red blood cells, granulocytes, platelets and other cells that dilute and mask the stem cells from being detected. This does not allow the quality and potency of the stem cells to be reliably measured. Methods 63 UCB segments and 10 UCB units plus segments were analyzed for the response of both primitive lympho-hematopoietic and primitive hematopoietic stem cells in both the TNC and MNC fractions. The samples were analyzed using a highly sensitive, standardized and validated adenosine triphosphate (ATP) bioluminescence stem cell proliferation assay verified against the colony-forming unit (CFU) assay. Dye exclusion and metabolic viability were also determined. Results Regardless of whether the cells were derived from a segment or unit, the TNC fraction always produced a significantly lower and more variable stem cell response than that derived from the MNC fraction. Routine dye exclusion cell viability did not correspond with metabolic viability and stem cell response. Paired UCB segments produced highly variable results, and the UCB segment did not produce similar results to the unit. Discussion The TNC fraction underestimates the ability and capacity of the stem cells in both the UCB segment and unit and therefore provides an erroneous interpretation of the of the results. Dye exclusion viability can result in false positive values, when in fact the stem cells may be dead or incapable of proliferation. The difference in response between the segment and unit calls into question the ability to use the segment as a representative sample of the UCB unit. It is apparent that present UCB processing and testing methods are inadequate to properly determine the quality and potency of the unit for release and use in a patient.